Which medication listed is an extended-release form of exenatide?

Bydureon is the extended-release formulation of exenatide, which is a medication used for the management of type 2 diabetes. It is designed to be injected once a week, allowing for more stable blood glucose control compared to its counterpart, Byetta, which is the immediate-release form that is administered twice daily.

The rationale behind the development of an extended-release version like Bydureon is to improve patient adherence to treatment regimens, as less frequent dosing can enhance convenience for individuals managing their diabetes. The extended-release formulation works by slowly releasing the active ingredient over time, leading to prolonged effects in regulating blood sugar levels.

In contrast, Byetta, Victoza, and Starlix serve different purposes or contain different active ingredients. Byetta is the immediate-release version of exenatide, Victoza is a different GLP-1 receptor agonist (liraglutide), and Starlix is a medication that stimulates insulin secretion but does not contain exenatide at all. Therefore, Bydureon is the correct choice as it specifically refers to the extended-release form of exenatide.